NCT04148066View on ClinicalTrials.gov

ctDNA Guided Treatment of Early Resistance to Targeted Treatment

NACompletedINTERVENTIONAL

Enrollment

104

Participants

Timeline

Start Date

July 17, 2019

Primary Completion Date

December 17, 2021

Study Completion Date

December 17, 2021

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DIAGNOSTIC_TEST

ctDNA blood sample

every six weeks during treatment and upon radiological progression blood will be drawn to analyse ctDNA with Avenio ctDNA (Expanded panel) to detect all known EGFR TKI resistance mechanisms.

Trial Locations (2)

1066 CX

The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam

Unknown

Erasmus MC, Universitair Medisch Centrum Rotterdam, Rotterdam

All Listed Sponsors

collaborator

Roche Pharma AG

INDUSTRY

lead

The Netherlands Cancer Institute

OTHER

NCT04148066 - ctDNA Guided Treatment of Early Resistance to Targeted Treatment | Biotech Hunter | Biotech Hunter